Pharmaceutical Technology
SEPTEMBER 28, 2022
The approvals include Keytruda plus chemotherapy as neoadjuvant treatment and then continued as a single agent for adjuvant treatment post-surgery in hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. This approval is based on KEYNOTE-564 trial data.
pharmaphorum
OCTOBER 14, 2021
Keytruda (pembrolizumab) can be used in combination with chemotherapy, with or without bevacizumab, to treat patients with persistent, recurrent or metastatic cervical cancer where the tumour expresses a certain level of PD-L1. 0.77]; p<0.0001) compared to chemotherapy, with or without bevacizumab, where tumours expressed PD-L1 (CPS ?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 4, 2023
The combination therapy can be used to treat la/mUC patients who do not qualify for cisplatin-containing chemotherapy. KEYTRUDA is an anti-PD-1 therapy developed by Merck, while Padcev has been developed by Astellas and Seagen. Results showed that patients treated with Padcev along with KEYTRUDA achieved a confirmed ORR of 68%.
pharmaphorum
MARCH 2, 2021
Keytruda had been granted accelerated approval in metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. This was based on data from response rate a durability of response rate data from the KEYNOTE-158 and KEYNOTE-028 trial.
European Pharmaceutical Review
JUNE 18, 2024
The US Food and Drug Administration (FDA) has approved the first anti-PD-1 therapy in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. In the placebo plus carboplatin and paclitaxel arm, PFS was 6.5
European Pharmaceutical Review
AUGUST 12, 2024
It is the first anti-PD-1 therapy approved for use together chemotherapy in adults who have primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status. The bispecific antibody has shown potential to generate “significant and sustained reductions in B-cell populations”.
Pharmaceutical Technology
AUGUST 5, 2022
Earlier, these patients received neoadjuvant or adjuvant chemotherapy. Merck Research Laboratories global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr said: “The approval offers patients with germline BRCA-mutated, HER2-negative early-stage breast cancer a new, much-needed treatment option.
Expert insights. Personalized for you.
59 
Let's personalize your content